Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–308 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Atorvastatin Clear all

Conditions: Avascular Necrosis
Interventions: Atorvastatin, MRI, Venipuncture, Placebo; Drug · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Lymphoma, Non-Hodgkin
Interventions: Atorvastatin; Drug
Lead sponsor: Dean Felsher; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 127
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 124 more

Conditions: Hyperlipoproteinemia Type III
Interventions: torcetrapib/atorvastatin, atorvastatin, fenofibrate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 22
States / cities: Anaheim, California • Huntington Beach, California • Orange, California + 18 more

Conditions: Atherosclerosis
Interventions: Atorvastatin, Rosuvastatin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer's Disease, Aging
Interventions: simvastatin, pravastatin; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dyslipidemia, Hypertension
Interventions: Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 51
States / cities: Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more

Conditions: Hearing Loss, Head and Neck Cancer
Interventions: Placebo, Atorvastatin; Other · Drug
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more

Conditions: Coronary Arteriosclerosis
Interventions: Atorvastatin, Pravastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 36
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 30 more

Conditions: Breast Cancer
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 35 Years to 55 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 7
States / cities: San Francisco, California • Newark, Delaware • Boston, Massachusetts + 4 more

Conditions: Pharmacokinetics
Interventions: ABT-335, Atorvastatin, Ezetimibe; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise; Drug · Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more

Conditions: Pain
Interventions: Succinylcholine; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Mixed Dyslipidemia
Interventions: ABT-335, rosuvastatin calcium, simvastatin, atorvastatin calcium; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Aortic Valve Stenosis
Interventions: atorvastatin (Lipitor); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Human Immunodeficiency Virus
Interventions: Aspirin, Atorvastatin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Hypercholesterolemia
Interventions: Atorvastatin suspension, Lipitor; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes
Interventions: Lapaquistat acetate and lipid-lowering therapy, Lipid-lowering therapy; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Tucson, Arizona • Artesia, California • Jacksonville, Florida + 15 more

Conditions: Healthy Participants
Interventions: Elecoglipron, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Healthy Participants
Interventions: AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Search by objective public record fields.

Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus

Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.

Rho Kinase in Patients With Atherosclerosis

Do HMG CoA Reductase Inhibitors Affect Abeta Levels?

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.

Statins and Breast Cancer Biomarkers

A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe

Risk Reduction for Alzheimer's Disease

Effect of Succinylcholine on Patients Using Statins

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

The Effect of Lipitor on Aortic Stenosis

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Bioavailability Study for New Atorvastatin Formulation

Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants